Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 7/20 | 0.58 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.54 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.54 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.44 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | USP7 | Q93009 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 2/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5836845 | 0.88 | MMP13 (0.62) | MMP13ENPP3ENPP1 | |
| SCHEMBL5836841 | 0.81 | MMP13 (0.53) | MMP13HSD17B1HSD17B2ENPP3ENPP1 | |
| SCHEMBL5837339 | 0.81 | ENPP3 (0.65) | MMP13HSD17B1HSD17B2ENPP3ENPP1 | |
| SCHEMBL5836215 | 0.78 | MMP13 (0.57) | MMP13HSD17B1HSD17B2ENPP3ENPP1 | |
| SCHEMBL12871327 | 0.77 | HSD17B1 (0.88) | HSD17B1HSD17B2ENPP3ENPP1USP7 | |
| SCHEMBL5835617 | 0.74 | MMP13 (1.00) | MMP13 | |
| SCHEMBL16670394 | 0.72 | LTA4H (0.53) | SCN9ACYP11B1CYP11B2 | |
| SCHEMBL5836277 | 0.72 | MMP13 (0.52) | MMP13HSD17B1HSD17B2ENPP3ENPP1 | |
| SCHEMBL4187927 | 0.71 | GRM5 (0.47) | MMP13ENPP3ENPP1NOTUMGRM5 | |
| SCHEMBL1004627 | 0.71 | ENPP3 (0.57) | MMP13HSD17B1HSD17B2ENPP3ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119201-B2 | Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER INC (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1501515-B1 | TRIARYL-OXY-ARYLOXY-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | PFIZER PROD INC (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20040006057-A1 | Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER PRODUCTS INC. | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006057-A1 | Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors | MMP8, MMP9, MMP1 | MMP13 15/4885HSD17B1 360/4885HSD17B2 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.